溶瘤腺病毒
病毒复制
基因敲除
溶瘤病毒
泛素
病毒学
癌症研究
病毒
免疫沉淀
细胞毒性
化学
细胞培养
体外
生物
复制(统计)
腺病毒科
细胞生物学
细胞
分子生物学
HEK 293细胞
腺病毒感染
MTT法
活力测定
生物标志物
病毒蛋白
作者
Boduan Xiao,Qingzhe Yang,Shichuan Hu,Jianchuan Hu,Zhongbing Qi,Yao Zhang,Yu Qin,Ping Cheng
出处
期刊:MedComm
[Wiley]
日期:2026-03-18
卷期号:7 (4): e70683-e70683
摘要
Oncolytic adenovirus (OAd) therapy is one of the effective treatment strategies for solid malignant tumors, and E1A is a requirement for adenovirus replication. Thus, it is very important to study how E1A regulates adenovirus replication. The p300 and E1A expression were detected by Western blot. The viral replication of OAd was detected by virus replication assay. The interaction between E1A and p300 was analyzed by immunofluorescence and immunoprecipitation assays. The therapeutic effect of OAd-shp300 was analyzed by MTT assay and animal experiments. The results indicated that OAd infection or E1A overexpression could reduce p300 expression, implying that OAd might reduce p300 expression via E1A, and p300 knockdown could enhance viral replication and cell cytotoxicity of OAd. Furthermore, E1A promoted viral replication of OAd via mediating p300 ubiquitination degradation to inhibit the IFI16/STING/IRF3/IFN-β signaling pathway. Additionally, OAd-shp300 induced highly efficient viral replication and potent antitumor activity both in vitro and in vivo. In this study, OAd can reduce p300 expression by promoting its ubiquitination via E1A, thereby enhancing viral replication and cell cytotoxicity. Therefore, this study can provide a biomarker for screening patients who are sensitive to OAd and new ideas for clinical tumor treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI